Considering dose in pharmacological therapies for heart failure - Authors' reply

Affiliations

¹ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
² Division of Cardiology, Los Angeles Medical Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
³ British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
⁴ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: ssolomon@bwh.harvard.edu.

Comment

Muthiah Vaduganathan et al. Lancet. 2021.

. 2021 Jan 23;397(10271):275.

doi: 10.1016/S0140-6736(21)00090-8.

¹ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
² Division of Cardiology, Los Angeles Medical Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
³ British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
⁴ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: ssolomon@bwh.harvard.edu.

No abstract available

Comment on

Considering dose in pharmacological therapies for heart failure.
Seedat Z, Itty K. Seedat Z, et al. Lancet. 2021 Jan 23;397(10271):274-275. doi: 10.1016/S0140-6736(21)00089-1. Lancet. 2021. PMID: 33485441 No abstract available.